Dan Skovronsky, Eli Lilly CSO
September 16, 2020 07:16 AM EDTUpdated September 17, 12:03 AM
R&D
Coronavirus

An­a­lysts are quick to pan Eli Lil­ly's puz­zling first cut of pos­i­tive clin­i­cal da­ta for its Covid-19 an­ti­body

John Carroll

Editor & Founder

Eli Lil­ly spot­light­ed a suc­cess for one of 3 dos­es of their close­ly-watched Covid-19 an­ti­body drug Wednes­day morn­ing. But an­a­lysts quick­ly high­light­ed some ob­vi­ous anom­alies …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

Pfiz­er’s mes­sage to in­vestors: The ship is steady­ing in 2025 (even if Wash­ing­ton is tur­bu­lent)

Chica­go’s biotech scene is grow­ing up. What’s fu­el­ing it?

UCB, No­var­tis say a Phase 2a Parkin­son's study failed

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Jazz Phar­ma­ceu­ti­cals CEO and co-founder Bruce Cozadd is re­tir­ing

A service from the Financial Times